Patents by Inventor Shih-Wei Lo

Shih-Wei Lo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220317408
    Abstract: An optical system affixed to an electronic apparatus is provided, including a first optical module, a second optical module, and a third optical module. The first optical module is configured to adjust the moving direction of a first light from a first moving direction to a second moving direction, wherein the first moving direction is not parallel to the second moving direction. The second optical module is configured to receive the first light moving in the second moving direction. The first light reaches the third optical module via the first optical module and the second optical module in sequence. The third optical module includes a first photoelectric converter configured to transform the first light into a first image signal.
    Type: Application
    Filed: June 21, 2022
    Publication date: October 6, 2022
    Inventors: Chao-Chang HU, Chih-Wei WENG, Chia-Che WU, Chien-Yu KAO, Hsiao-Hsin HU, He-Ling CHANG, Chao-Hsi WANG, Chen-Hsien FAN, Che-Wei CHANG, Mao-Gen JIAN, Sung-Mao TSAI, Wei-Jhe SHEN, Yung-Ping YANG, Sin-Hong LIN, Tzu-Yu CHANG, Sin-Jhong SONG, Shang-Yu HSU, Meng-Ting LIN, Shih-Wei HUNG, Yu-Huai LIAO, Mao-Kuo HSU, Hsueh-Ju LU, Ching-Chieh HUANG, Chih-Wen CHIANG, Yu-Chiao LO, Ying-Jen WANG, Shu-Shan CHEN, Che-Hsiang CHIU
  • Patent number: 11397302
    Abstract: An optical system affixed to an electronic apparatus is provided, including a first optical module, a second optical module, and a third optical module. The first optical module is configured to adjust the moving direction of a first light from a first moving direction to a second moving direction, wherein the first moving direction is not parallel to the second moving direction. The second optical module is configured to receive the first light moving in the second moving direction. The first light reaches the third optical module via the first optical module and the second optical module in sequence. The third optical module includes a first photoelectric converter configured to transform the first light into a first image signal.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: July 26, 2022
    Assignee: TDK TAIWAN CORP.
    Inventors: Chao-Chang Hu, Chih-Wei Weng, Chia-Che Wu, Chien-Yu Kao, Hsiao-Hsin Hu, He-Ling Chang, Chao-Hsi Wang, Chen-Hsien Fan, Che-Wei Chang, Mao-Gen Jian, Sung-Mao Tsai, Wei-Jhe Shen, Yung-Ping Yang, Sin-Hong Lin, Tzu-Yu Chang, Sin-Jhong Song, Shang-Yu Hsu, Meng-Ting Lin, Shih-Wei Hung, Yu-Huai Liao, Mao-Kuo Hsu, Hsueh-Ju Lu, Ching-Chieh Huang, Chih-Wen Chiang, Yu-Chiao Lo, Ying-Jen Wang, Shu-Shan Chen, Che-Hsiang Chiu
  • Publication number: 20220227728
    Abstract: The present invention discloses a series of nuclear medicine tracers that are combined with brain microtubule-associated protein Tau targeting compounds to produce a group of compounds of nuclear medicine that can be utilized for imaging of microtubule-associated protein Tau. When the positrons released by the decay encounter the electrons of the cells in the sample, utilizing the positron decay characteristics of fluorine-18 or iodine-124 isotope to generate mutual destruction reactions, a pair of opposite gamma rays is formed which are imaged by positron emission tomography. The compounds can be applied for the in vivo detection of microtubule-associated protein Tau deposits in the brain. The invention provides a strategy for diagnosis of Alzheimer's disease and a method to measure the efficacy of therapeutic drugs targeting microtubule-associated protein Tau.
    Type: Application
    Filed: January 19, 2021
    Publication date: July 21, 2022
    Inventors: MING-HSIN LI, KAI-HUNG CHENG, SHENG-NAN LO, SHIH-WEI LO, YUAN-RUEI HUANG, JENN-TZONG CHEN
  • Patent number: 11369702
    Abstract: Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95° C. by adding an aqueous solution.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: June 28, 2022
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C
    Inventors: Ming-Hsin Li, Shih-Wei Lo, Sheng-Nan Lo, Shih-Ying Lee, Su-Jung Chen
  • Publication number: 20220089574
    Abstract: The structure and preparation method of a compound D-L2(-B)-L1-A is disclosed, A is a physiologically and pharmacologically active molecule that physically binds to a specific biological molecule or receptor; L1 is a variable structure with the molecular connection activity at both ends connecting to A and L2; L2 is a variable structure, which has three-terminal molecular connection activity connecting to L1, D and B; B is a physiologically and pharmacologically active molecule that binds to albumin, changing the A molecule in the body cyclic characteristics; D is a polycarboxylic macrocyclic structure that binds to radioisotopes; D-L2(-B)-L1-A compound can be used to express chemokine receptor 4 (CXCR4) receptors on cells, tissues, and/or organs, and after binding with radionuclides, it is suitable for detection of CXCR4 protein binding in vitro, detection of CXCR4 cell binding in vitro or detection of CXCR4 expression in in vivo animal imaging.
    Type: Application
    Filed: September 22, 2020
    Publication date: March 24, 2022
    Inventors: MING-HSIN LI, SHENG-NAN LO, SHIH-WEI LO, SHIH-YING LEE, SU-JUNG CHEN, WEI-LIN LO, MING-WEI CHEN, YUAN-RUEI HUANG
  • Patent number: 11202577
    Abstract: A system and method for monitoring cardiovascular and brain functions in combination with a physiological detection device, which uses a smart wearable device to detect physiological data such as heart rate and pulse pressure of a user, and transmits the physiological data to an arithmetic function. An electronic device in which a preset function and a calculation formula are built in, and the physiological data can be converted into corresponding determination parameters to monitor the possibility and risk of cardiovascular diseases and neurodegenerative diseases.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 21, 2021
    Inventors: Ming-Hsin Li, Kai-Hung Cheng, Shih-Wei Lo
  • Publication number: 20210369878
    Abstract: Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95° C. by adding an aqueous solution.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 2, 2021
    Inventors: MING-HSIN LI, SHIH-WEI LO, SHENG-NAN LO, SHIH-YING LEE, SU-JUNG CHEN
  • Publication number: 20210121074
    Abstract: A system and method for monitoring cardiovascular and brain functions in combination with a physiological detection device, which uses a smart wearable device to detect physiological data such as heart rate and pulse pressure of a user, and transmits the physiological data to an arithmetic function. An electronic device in which a preset function and a calculation formula are built in, and the physiological data can be converted into corresponding determination parameters to monitor the possibility and risk of cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 29, 2021
    Inventors: MING-HSIN LI, KAI-HUNG CHENG, SHIH-WEI LO
  • Publication number: 20210121585
    Abstract: The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 29, 2021
    Inventors: MING-HSIN LI, Sheng-Nan Lo, Shih-Wei Lo, Shih-Ying Lee, Su-Jung Chen, Shih-Min Wang, Ming-Wei Chen, Wei-Lin Lo
  • Publication number: 20200129646
    Abstract: A radioactive labeled long-acting peptide-targeting pharmaceutical and production method, in which the peptide targeted pharmaceutical is firstly dissolved in a solution, followed by labeling the radioactive at a high temperature, and the dosage of the pharmaceutical with radioactive labeling is expected to be reduced and labeling efficiency is improved, and no further purification by filtration is required, which shortens the preparation process and reduces personnel exposure in the working environment. The radioactive labeled long-acting peptide-targeting pharmaceutical can increase the specific binding capacity of tumors and reduce the non-specific accumulation in normal tissues. It can be applied to the field of tumor and nuclear medicine for diagnosis and treatment of tumors and/or tumor metastases with efficacy and precision treatment.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 30, 2020
    Inventors: Ming-Hsin Li, Chih-Hsien Chang, Su-Jung Chen, Shih-Ying Lee, Sheng-Nan Lo, Ming-Wei Chen, Yuan-Ruei Huang, Chun-Fang Feng, Shih-Wei Lo, Cheng-Hui Chuang
  • Publication number: 20200078478
    Abstract: A PSMA targeting peptide derivative for radiotherapy, which is a structural molecule developed for diagnosis or treatment of prostate cancer, as prostate-specific membrane antigen (PSMA) is a protein present on the surface of healthy prostate cells, which is often at a high level of expression on the surface of prostate cancer cells, and the molecular composition of PSMA inhibitor is mainly composed of glutamic acid, urea and lysine, in addition to the linker of the present invention, PSMA inhibitor can be combined with a chelating agent and truncated Evans Blue, which can be labeled with radionuclides Ga-67, Ga-68, In-111, Lu-177, Cu-64 or Y-90, used for image analysis and analysis of human prostate cancer tumor pattern as a new PSMA targeting peptide receptor radionuclide therapy (PRRT), and which has a longer half-life in vivo and is featured by specific binding of PSMA for radiotherapy diagnosis or treatment.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 12, 2020
    Inventors: Ming-Hsin Li, Ming-Wei Chen, Shin-Min Wang, Shih-Wei Lo, Chun-Fang Feng, Cheng-Hui Chuang, Sheng-Nan Lo